Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep 6;16(1):722.
doi: 10.1186/s12885-016-2696-0.

The pretreatment Controlling Nutritional Status (CONUT) score is an independent prognostic factor in patients with resectable thoracic esophageal squamous cell carcinoma: results from a retrospective study

Affiliations

The pretreatment Controlling Nutritional Status (CONUT) score is an independent prognostic factor in patients with resectable thoracic esophageal squamous cell carcinoma: results from a retrospective study

Takahiro Toyokawa et al. BMC Cancer. .

Abstract

Background: The purpose of this study was to investigate the impact of the Controlling Nutritional Status (CONUT) score on survival compared with the platelet to lymphocyte ratio (PLR), the neutrophil to lymphocyte ratio (NLR), and the Glasgow Prognostic Score (GPS) in patients with resectable thoracic esophageal squamous cell carcinoma (ESCC).

Methods: One hundred eighty-five consecutive patients who underwent subtotal esophagectomy with curative intent for resectable thoracic ESCC were retrospectively reviewed. Time-dependent receiver operating characteristic curve analyses for 3-year overall survival (OS) as the endpoint were performed, and the maximal Youden indices were calculated to assess discrimination ability and to determine the appropriate cut-off values of CONUT, PLR, and NLR. The patients were then classified into high and low groups based on these cut-off values. Correlations between CONUT and other clinicopathological characteristics were analyzed. Prognostic factors predicting overall survival (OS) and relapse-free survival (RFS) were analyzed using Cox proportional hazards models.

Results: The areas under the curve predicting 3-year OS were 0.603 for CONUT, 0.561 for PLR, 0.564 for NLR, and 0.563 for GPS. The optimal cut-off values were two for the CONUT score, 193 for PLR, and 3.612 for NLR. The high-CONUT group was significantly associated with lower BMI, high-PLR, high-NLR, and GPS1/2 groups. On univariate analysis, high-CONUT, high-PLR, high-NLR, and GPS 1/2 groups were significantly associated with poorer OS and RFS. Of these factors, multivariate analysis revealed that only the CONUT score was an independent prognostic factor for OS (HR 2.303, 95 % CI 1.191-4.455; p = 0.013) and RFS (HR 2.163, 95 % CI 1.139-4.109; p = 0.018).

Conclusions: The CONUT score was an independent predictor of OS and RFS before treatment and was superior to PLR, NLR, and GPS in terms of predictive ability for prognosis in patients with resectable thoracic ESCC.

Keywords: Controlling nutritional status; Esophageal cancer; Esophagectomy; Nutrition; Prognostic factor.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Kaplan-Meier survival curves of overall survival (OS) and relapse-free survival (RFS) in patients with resectable thoracic ESCC. a The 3- and 5-year OS rates are 72.0 % and 63.6 % in the low-CONUT group and 35.3 and 35.3 % in the high-CONUT group. b The 3- and 5-year RFS rates are 65.3 and 59.5 % in the low-CONUT group and 35.3 and 35.3 % in the high-CONUT group. c The 3- and 5-year OS rates are 72.1 and 62.6 % in the low-PLR group and 52.1 and 52.1 % in the high-PLR group. d The 3- and 5-year RFS rates are 65.4 and 59.5 % in the low-PLR group and 49.3 and 45.5 % in the high-PLR group. e The 3- and 5-year OS rates are 72.1 and 63.3 % in the low-NLR group and 43.5 and 43.5 % in the high-NLR group. f The 3- and 5-year RFS rates are 65.0 and 59.6 % in the low-NLR group and 44.6 and 39.0 % in the high-NLR group. g The 3- and 5-year OS rates are 71.4 and 63.9 % in the GPS 0 group and 32.7 and 16.3 % in the GPS 1/2 group. h The 3- and 5-year RFS rates are 64.8 and 59.8 % in the GPS 0 group and 34.3 and 17.1 % in the GPS 1/2 group
Fig. 2
Fig. 2
Kaplan-Meier survival curves of overall survival (OS) and relapse-free survival (RFS) according to the CONUT score in patients with preoperative treatment (a OS, p = 0.008; b RFS, p = 0.010) and in patients without preoperative treatment (c OS, p = 0.002; d RFS, p = 0.009)

Similar articles

Cited by

References

    1. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381(9864):400–12. doi: 10.1016/S0140-6736(12)60643-6. - DOI - PubMed
    1. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12(7):681–92. doi: 10.1016/S1470-2045(11)70142-5. - DOI - PubMed
    1. Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907) Ann Surg Oncol. 2012;19(1):68–74. doi: 10.1245/s10434-011-2049-9. - DOI - PubMed
    1. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84. doi: 10.1056/NEJMoa1112088. - DOI - PubMed
    1. Gronnier C, Trechot B, Duhamel A, et al. Impact of neoadjuvant chemoradiotherapy on postoperative outcomes after esophageal cancer resection: results of a European multicenter study. Ann Surg. 2014;260(5):764–71. doi: 10.1097/SLA.0000000000000955. - DOI - PubMed

MeSH terms

Substances